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Neuroinflammation is known to have a pivotal role in the pathogenesis of Alzheimer’s
disease (AD), and curcumin has been reported to have therapeutical effects on
AD because of its anti-inflammatory effects. Curcumin is not only a potent PPARγ
agonist, but also has neuroprotective effects on cerebral ischemic injury. However,
whether PPARγ activated by curcumin is responsible for the anti-neuroinflammation and
neuroprotection on AD remains unclear, and needs to be further investigated. Here,
using both APP/PS1 transgenic mice and beta-amyloid-induced neuroinflammation in
mixed neuronal/glial cultures, we showed that curcumin significantly alleviated spatial
memory deficits in APP/PS1 mice and promoted cholinergic neuronal function in vivo
and in vitro. Curcumin also reduced the activation of microglia and astrocytes, as
well as cytokine production and inhibited nuclear factor kappa B (NF-κB) signaling
pathway, suggesting the beneficial effects of curcumin on AD are attributable to the
suppression of neuroinflammation. Attenuation of these beneficial effects occurred when
co-administrated with PPARγ antagonist GW9662 or silence of PPARγ gene expression,
indicating that PPARγ might be involved in anti-inflammatory effects. Circular dichroism
and co-immunoprecipitation analysis showed that curcumin directly bound to PPARγ and
increased the transcriptional activity and protein levels of PPARγ. Taking together, these
data suggested that PPARγ might be a potential target of curcumin, acting to alleviate
neuroinflammation and improve neuronal function in AD.
Keywords: Alzheimer’s disease, curcumin, neuroinflammation, peroxisome proliferator-activated receptor-
gamma, NF-κB
INTRODUCTION
Alzheimer’s disease (AD) is a chronic neurodegenerative disease and the most common
form of dementia. It is characterized by selective neuronal loss, progressive memory, and
cognitive impairment (Campbell and Gowran, 2007). The molecular pathogenesis of AD involves
extracellular deposition of beta-amyloid (Aβ) peptides in the hippocampus. Aggregated Aβ
Liu et al. Curcumin Attenuates Beta-Amyloid-Induced-Neuroinflammation in AD
can trigger microglia and astrocytes activation, leading to
the production of inflammatory factor, including nitric oxide
(NO), tumor necrosis factor-α (TNF-α), interleukins (ILs),
and prostaglandins, in the vicinity of Aβ peptides, which
may cause neuronal death (Akiyama et al., 2000; Kitazawa
et al., 2004). This inflammatory response increases as the
disease progresses, which eventually leads to neurodegeneration.
Moreover, epidemiological study suggested that inflammation is
a key player in the pathophysiology of AD (Szekely et al., 2004).
Consistently, non-steroidal anti-inflammatory drugs (NSAIDs)
suppress neuroinflammatory response in a dose-dependent
manner and reduce behavioral deficits in transgenic animal
models of AD (McGeer and McGeer, 2007). These studies
demonstrate the role of inflammation in the pathogenesis of AD
and provide the rational of anti-inflammatory therapy.
Many studies have been conducted to determine the potential
therapeutics to ameliorate AD. Increasing studies have shown
that curcumin has therapeutic effects for AD (Cole et al., 2007).
Curcumin is known to reduce Aβ oligomer and fibril formation
(Yang et al., 2005; Xiong et al., 2011), inhibit the neurotoxicity
of Aβ in the brain (Jiang et al., 2012; Sun et al., 2014), suppress
Aβ-induced inflammation (Lim et al., 2001; Lu et al., 2014) and
markedly reduce the levels of IL-1β (Griffin et al., 1998) and
iNOS (Begum et al., 2008) in transgenic mouse brain. Clinical
trial demonstrated that curcumin has beneficial on AD patients
(Baum et al., 2008). Despite the promising prospects, the exact
mechanism which curcumin exerts its neuroprotection largely
remains unknown.
Furthermore, a mechanistic study showed that anti-
inflammatory effects can be achieved by inhibiting the nuclear
factor kappa B (NF-κB) (Becaria et al., 2003) and ERK (Giri et al.,
2004) signaling pathways, which can be regulated by peroxisome
proliferator-activated receptor gamma (PPARγ). The actions
of PPARγ and its agonists in AD have been well documented
over the past decade. Treatment with PPARγ agonist lead to the
reduced Aβ production, neuroinflammation, and improvement
of cognitive function (Sodhi et al., 2011; Mandrekar-Colucci
et al., 2012). One proposed mechanism for the actions of
PPARγ is that the anti-inflammatory effects of PPARγ linked
to cognitive impairment. Our previous study demonstrated
that curcumin is a potent PPARγ agonist (Liu et al., 2011), and
has neuroprotective effects on ischemic injury in vitro and in
vivo (Liu et al., 2013, 2014). However, whether the activation of
PPARγ of curcumin is responsible for its neuroprotection on AD
remains unclear and needs to be further investigated.
MATERIALS AND METHODS
Chemicals and Reagents
Curcumin, GW9662, Aβ1–42, and Griess reagent were purchased
from Sigma. Dulbecco’s Modified Eagle Medium Nutrient
Mixture F-12 (DMEM/F-12), fetal bovine serum (FBS), and Opti-
Minimum Essential Medium (MEM) were producted by Gibco.
PPARγ siRNA was synthesized by Invitrogen. Lipofectamine
LTX and Plus Reagent was produced by Invitrogen. Choline
acetyltransferase (ChAT), glial fibrillary acidic protein (GFAP),
Iba-1, NF-κB p65, IκBα, and PPARγ antibodies were obtained
from Abcam. IL-1β, TNF-α, and COX-2 ELISA kits were
purchased from R&D Company. A choline/acetylcholine (Ach)
assay kit was supplied by Abcam. AChATELISA kit was obtained
from MyBioSource Inc. A PPARγ transcription factor assay kit
and PPARγ ligand binding domain (human recombinant) were
purchased from Cayman Chemical. A co-immunoprecipitation
(Co-IP) kit produced by Pierce was used, and LDH assay
kit was supplied by Nanjing Jiancheng Bioengineering
Institute.
Animals and Treatment
Transgenic mice overexpress Swedish mutant AβPP695 and
deletion of exon-9 mutant PS1 (APPswe/PS119). Mice were
housed in a 12 h light/dark room at 24◦C in the Animal
Center of Chinese Academy of Medical Sciences. 150mg/kg
of curcumin and 4mg/kg of PPARγ inhibitor GW9662
(Garrido-Gil et al., 2012) were dissolved in 10% dimethyl
sulfoxide (DMSO), and intraperitoneally injected to APP/PS1
double-transgenic 8-month-old mice daily for 4 consecutive
weeks. The animal experiments were approved by the animal
experimental ethics committee of China-Japan Friendship
Hospital.
Hippocampal Neuronal/Glial Culture and
Treatment
Primary hippocampus neuronal/glial cultures were obtained
from the brain of rat embryos at 19 d of gestation (Beijing Vital
River Laboratory Animal Technology Co. Ltd., Beijing, China).
The procedure was approved by the Animal Ethic Committee of
China-Japan Friendship Hospital. In brief, the hippocampus was
isolated, and then incubated with 0.25mg/mL trypsin at 37◦C
for 30min, gently triturated in DMEM/F-12, and centrifuged
to collect the cells. Dissociated cells were plated in dishes
coated with 10mg/mL poly-D lysine and grown in DMEM/F-
12 with 10% FBS, 1mM sodium pyruvate, 0.1mM non-essential
amino acids, 2mM L-glutamic acid, 100 U/mL penicillin, and
100µg/mL streptomycin in incubator with 95% air/5% CO2 at
37◦C. Cultures grown for 7 d in vitro were used for experiments.
Aβ1–42 solution (dissolved in PBS) was placed at 37
◦Cwith gentle
shaking for 72 h to allow the peptide to aggregate. Cells were
pre-treated with 10µM curcumin, and 25µMAβ1–42 was added
to the media 1 h later, the cells were harvested 24 h later. To
inhibit PPARγ function, 1µM GW9662 (dissolved in DMSO)
was incubated with the cultures or PPARγ siRNA was transfected
to cells 1 h prior to Aβ1–42 treatment, and the cells were harvested
24 h later.
Silencing of PPARγ by RNAi
Mixed neuronal/glial cultures were grown in a flask to ∼60%
confluence, and transfected with an optimized concentration
of PPARγ siRNA. Transfection was performed using the
Lipofectamine LTX and Plus Reagent and 25 nM appropriate
PPARγ siRNA, according to the manufacturer’s instructions.
Transfection was conducted 1 h before Aβ1–42 treatment. Whole
cell lysates were then prepared, and PPARγ knockdown was
confirmed by western blot analysis.
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Morris Water Maze Test
Spatial learning and memory of mice were assessed by the Morris
water maze (Institute of Materia Medica, Chinese Academy of
Medical Sciences and Peking Union Medical College, Beijing,
China) after the mice had received curcumin for continuous 8
weeks. TheMorris watermaze test was performed in a round pool
(diameter 120 cm and depth 40 cm) filled with nontoxic opaque
water (Hernandez-Perez et al., 2015; Singh and Kumar, 2015).
The water maze was divided into four quadrants. A platformwith
diameter of 10 cm was placed in the pool. The water was filled in
the pool until the platform was 2 cm below the water surface. The
water temperature was maintained at about 23◦C. The protocol
was fixed and maintained throughout four acquisition trials,
except for randomly selecting starting point. At the start of each
trial, each mouse was allowed to swim in the water at one of
the four quadrants for a maximum of 120 s to find the platform.
After finding the platform, the mouse was kept on the platform
for 30 s, and would be placed on the platform for 30 s. Each
mouse received four trials every day. The latency to find the
platform (escape latency), the swimming distance, and swimming
speed were recorded. The training period was conducted for 5
consecutive days in which the platform was kept as the same. The
latency to escape was calculated as the average time to find the
platform of the four trials within 1 d.
Memory retention was evaluated on day 6 with a probe trial
in which the platform was removed. The mice were placed in
the pool and allowed to swim freely for 120 s and the crossing
number of the platform and time of mouse in the destination
were recorded.
Immunohistochemical Analysis
Mice were anesthetized with hydrate chloral and perfused via
the ascending aorta first with 0.9% saline and then followed
by 0.1M PBS (pH 7.4), which contains 4% paraformaldehyde.
Then the whole brains were removed and fixed in the 0.1M
PBS (pH 7.4) containing 4% paraformaldehyde and 30% sucrose
for 4 h. The brains were cut into sections of 40-µm. Six serial
sections were taken and incubated with the ChAT, GFAP, or Iba-
1 antibodies, respectively. And then the sections were incubated
with the biotinylated secondary antibodies for 90 min. The
immunoreactivity was visualized by 0.01% hydrogen peroxidase
and 0.03% 3, 3′-diaminobenzidine (DAB). The light microscopy
(NIKON E600, Japan) were used to observe sections, and the
intensity of the stained area of each group was analyzed using an
Image-Pro plus system (Media Cybernetics, Silver Spring, MD,
USA). All evaluations were performed by a researcher blind to
the experimental design.
ELISA Assay of Inflammatory Mediators
Immediately after mice were decapitated, hippocampi
were isolated, dissected, homogenized and centrifuged, the
supernatant was collected. For cytokine assay in the cell media,
the culture supernatants were collected. IL-1β, TNF-α, and COX-
2 were measured by ELISA kits according to the manufacturer’s
instructions (Spatuzza et al., 2014).
Western Blot Assay
Mouse hippocampus and cells were lysed on ice for 15min in
lysis buffer, which then were centrifuged at 12,000 g at 4◦C for
15min to collect the supernatants. Protein concentration was
measured with Bradford protein assay. Samples containing 50µg
proteins were loaded with loading buffer and separated by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The separated protein transferred to PVDF membranes
and blocked in 5% skim milk-TBST (20mM Tris-HCl, 500mM
NaCl, 0.1% Tween 20) for 1 h. GFAP, Mac-1, NF-κB p65, IκBα,
and PPARγ primary antibodies (dilution again) were added
in 5% skim milk-TBST, and incubated overnight at 4◦C. The
membranes were incubated with secondary antibody in TBST
for 2 h at room temperature. The immunoblot was detected with
a LAS3000 chemiluminescence system (Fujifilm, Tokyo, Japan),
and the densities of the bolt bands were quantified with Gel-Pro
Analyzer 4.0 software.
Ach and ChAT Assay
The Ach levels were measured by a choline/Ach assay
kit according to the manufacturer’s instructions. In brief,
the hippocampus was lysed in choline assay buffer by
homogenization on ice. Choline assay buffer (46µL), choline
probe (2µL), and choline enzyme mix (2µL) were combined
to prepare a reaction mixture. Approximately 50µL of sample
was added and incubated for 30 without exposure to light. The
absorbance was measured at the wavelength 570 nm.
ChAT assay was performed using a ChAT ELISA kit following
the manufacturer’s instructions. In brief, the hippocampi or
cells were lysed in PBS with an ultrasonic cell disrupter to
prepare the samples. Lysates (100µL) were added to each well.
Approximately 100µL of Detection Reagent A or Detection
Reagent B was added to the wells, which were then incubated.
After adding 50µL of Stop Solution, the plates were immediately
read at 450 nm.
Cell Immunocytochemistry and
Immunofluorescence Assay
Cells were fixed with 4% paraformaldehyde on cover ships at
room temperature for 15min and washed with PBS for three
times. The cells were permeabilized with PBS containing 0.1%
Triton X-100 for 10min, and blocked in 3% normal goat serum
for 2 h. The cells were incubated overnight with GFAP (1:500)
or Iba-1 (1:500). Cells were subsequently incubated with FITC-
conjugated affinipure secondary antibody (1:250). Fluorescent
intensity was imaged with an Olympus FV1000 (Olympus,
Tokyo, Japan).
PPARγ Transcriptional Activity Assay
PPARγ transcriptional activity was tested by a PPARγ
transcription factor assay kit, which is a sensitive method
for detecting specific DNA binding transcription factor activity
in nuclear extracts. A specific double-stranded DNA sequence
containing PPRE was immobilized onto the bottom of the well
of a 96-well plate. PPARγ transcriptional activity assay was
performed according to the manufacturer’s protocol. In brief,
90µL of complete transcription factor binding assay buffer
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was added to the plate, followed by 10µL of nuclear extracts,
which were prepared using a nuclear-cytosol extraction kit. One
hundred microliters of diluted PPARγ primary antibody (1:100)
was added, and incubated for 1 h at room temperature. HRP
conjugate secondary antibody was added and incubated for 1 h
at room temperature. One hundred microliters of transcription
factor developing solution was added to the samples, and
incubated for 30min with gentle agitation without light. After
adding the stop solution, the absorbance was read at 450 nm.
Measurement of LDH Releasing
The culture media were collected, and neuronal injury was
assessed by measurement of LDH releasing using LDH kit. The
optical density was read at 492 nm. Data were expressed as
percentage of optical density of control cells.
Nitrite Assay
NO production was determined by measuring the amount
of nitrite (NO−2 ) accumulated in supernatants of mixed
neuronal/glial cultures, which was detected by Griess assay as
described previously.
Co-IP Assay
Nuclear extracts of primary cultured cells were prepared using
nuclear-cytosol or a membrane extraction kit. The Co-IP assay
was conducted according to the protocol of Co-IP kit. Purified
PPARγ (300µg) antibody was immobilized in 100µL antibody
coupling gel. Samples (300µg proteins) were incubated with
gentle shaking for 2 h. The immunoprecipitated complexes were
eluted three times with elution buffer, and then subjected to SDS-
PAGE. The blot was transferred to a PVDFmembrane, incubated
with NF-κB or PPARγ antibody, respectively, and detected by an
enhanced LAS3000 chemiluminescence system.
Circular Dichroism (CD)
PPARγ protein were dissolved in phosphate buffer (pH 7.40,
0.01 M, I = 0.1) to the concentration of 6µM. Curcumin was
dissolved in 1.2µM solution with methanol with gently shaken.
The stock solutions of PPARγ and curcumin were mixed at the
ratio of 1:5 (v:v), and detected 5min later. CD spectra were
measured on Jasco-J815 CD spectrometer equipped with a Jasco
PTC-423S/15 temperature controller between 260 and 200 nm
using a 10mm cuvette at 37◦C.
Statistical Analysis
Statistical analysis was performed with SPSS version 21.0. All data
were presented as the mean± standard deviation (SD). Statistical
analysis was carried out on three or more groups using one-way
analysis of variance (ANOVA) and multiple comparison tests.
Values of P < 0.05 were considered statistically significant.
RESULTS
Curcumin Alleviated Spatial Learning and
Memory Deficits in APP/PS1 Mice
Memory deficits were started to show in the 8-month-old
APP/PS1 transgenic mice as indicated by longer escape latencies
in Morris water maze test (Figure S1) and Aβ accumulation
in the hippocampi (Figure S2) was also observed, suggesting
that the APP/PS1 transgene caused memory deficits in mice.
Curcumin treatment was initiated when APP/PS1 double-
transgenic mice were 8 months old. Curcumin markedly
decreased the escape latency from day 3 to 5 in the training
experiment (Figure 1A). In the probe test, the memory of
APP/PS1 mice significantly decreased, such as decreased number
of platform crossing, time spent in the target quadrant, and
increased travel distances. Curcumin remarkably increased
platform crossing number and time spent in the target
quadrant, and decreased the travel distance (Figures 1B–D).
The improvement in memory function was attenuated by
co-administration of GW9662, an inhibitor of PPARγ. Our
pilot study showed that intraperitoneally injection of GW9662
(4mg/kg, dissolved in 10% DMSO) alone daily for 5 weeks
did not influence memory (Figure S3) and neuronal function
of AD mice (Figure S4). These data suggest that curcumin
exert neuroprotective effects on memory deficits of APP/PS1
transgenic mice, and that the neuroprotection of curcumin on
AD is closely related to PPARγ.
Curcumin Protected Cholinergic Neurons
in APP/PS1 Mice
Cholinergic neurons play a key role in memory function, and
the progressive disruption of cholinergic function underlies
much of the short-term memory loss observed in AD. The
activity of the ChAT transferase enzyme responsible for the
synthesis of Ach also decreased in AD. Immunohistochemical
and ELISA assays showed that both ChAT-positive cells and
ChAT levels declined in the hippocampi of APP/PS1 mice, and
increased ChAT-positive cells and ChAT levels were observed
upon curcumin treatment (Figures 2A,B). ChAT dysfunction
led to the reductions in Ach in the hippocampus, which was
reversed and elevated by curcumin treatment (Figure 2C). Co-
administration of GW9662 attenuated the beneficial effects of
curcumin on cholinergic neurons in the hippocampi of APP/PS1
mice (Figure 2). These data further indicate that PPARγ was
involved in the neuroprotection of curcumin on cholinergic
neurons in vivo.
Curcumin Protected Cholinergic Neurons
in Mixed Neuronal/Glial Cultures
We further investigated the neuroprotective effects of curcumin
treatment on cholinergic neurons in vitro. As shown in Figure 3,
ChAT levels were markedly reduced in Aβ1–42-challenged mixed
neuronal/glial cultures. Pre-treatment of curcumin increased
ChAT levels. LDH is an important marker of neuronal injury. In
the present study, Aβ1–42 caused neuronal death by activating the
inflammatory response, as indicated by elevated LDH levels in the
media, suggesting increased cell destruction. However, neuronal
death was alleviated by curcumin, which resulted in decreased
LDH. The neuroprotection of curcumin was reversed by the
treatment of GW9662 or silence of PPARγ. Treatment of cells
with GW9662 or PPARγ siRNA alone did not affect cholinergic
neuronal function (Figure S5). These results suggested PPARγ
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FIGURE 1 | Curcumin alleviates spatial learning and memory deficits in APP/PS1 mice. Curcumin 150mg/kg and PPARγ inhibitor GW9662 4mg/kg were i.p.
injected to APP/PS1 double-transgenic mice for 4 consecutive weeks, and the learning and memory ability was accessed by Morris water maze test. (A) The
latencies of mice to find the destination. (B) Number of platform crossing in probe test. (C) Time in the target quadrant in probe test. (D) Travel distance in probe test.
Results were expressed as mean ± SD. **P < 0.01 vs. WT mice, #P < 0.05, ##P < 0.01 vs. APP/PS1 transgenic mice, 1P < 0.05 vs. curcumin treated mice.
n = 10 in each group.
FIGURE 2 | Curcumin protected cholinergic neurons in hippocampus of APP/PS1 double transgenic mice. Curcumin 150mg/kg and PPARγ inhibitor
GW9662 4mg/kg were i.p. injected to APP/PS1 double-transgenic mice for 4 consecutive weeks. (A) Immunohistochemistry of ChAT in hippocampus.
Representative sections of hippocampus from five mice were shown. (B) ELISA assay of ChAT. The results were obtained from six independent experiments. (C)
Colorimetric analysis of Ach. The results were obtained from six independent experiments. Results were expressed as mean ± SD. **P < 0.01 vs. WT mice,
##P < 0.01 vs. APP/PS1 transgenic mice, 1P < 0.05, 11P < 0.01 vs. curcumin treated mice.
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FIGURE 3 | Curcumin protected cholinergic neurons in mixed neuron/glia cultures. Mixed neuron/glia cultures were pre-treated with curcumin 10µM, 1 h
later, Aβ1–42 25µM was added to the mixed cultures. GW9662 1µM was added into the cultures or cells were transfected with PPARγ siRNA 1h before Aβ1–42
treatment. (A) ELISA assay of ChAT. The results were obtained from six independent experiments. (B) LDH releasing to the culture medium. Data were expressed as
mean ± SD with six individual experiments. **P < 0.01 vs. control cells, #P < 0.05, ##P < 0.01 vs. Aβ1–42-challenged cells,
1P < 0.05, 11P < 0.01 vs. curcumin
treated cells.
is involved in the beneficial effects of curcumin on cholinergic
neurons in vitro.
Curcumin Suppressed the
Neuroinflammatory Response in APP/PS1
Mice
Aβ can activate both microglia and astrocytes, which produce
multiple inflammatory mediators. Our results show that
the inflammatory response in the hippocampi of APP/PS1
mice was manifested by overproduction of TNF-α, IL-
1β, COX-2, and NO. Treatment of mice with curcumin
markedly suppressed the production of these toxic mediators
(Figures 4A–D). We then examined the possible activation
of microglia and astrocytes in the hippocampi of mice. In
the WT mice, a small number of Iba1-positive microglia
and GFAP-positive astrocytes were distributed throughout
the hippocampus. Iba1-positive microglia with enlarged cell
bodies increased, and the accumulation of GFAP-positive
astrocytes with enlarged cell bodies and short processes was also
noted in the hippocampi of APP/PS1 mice (Figures 4E,F).
Furthermore, western blot showed that the expression
of GFAP and Iba-1 markedly increased in APP/PS1 mice
(Figures 4G,H). These morphological and expression changes
strongly suggest that both microglia and astrocytes distributed
in the hippocampus were activated upon Aβ stimulation.
Curcumin treatment suppressed neuroinflammation, as
indicated by the reduced production of inflammatory mediators,
decreased number of GFAP- and Iba-1-positive cells, and
expression in the hippocampus. As expected, GW9662
attenuated the anti-neuroinflammatory effects of curcumin
(Figure 4).
Curcumin Inhibited Neuroinflammation in
Mixed Neuronal/Glial Cultures
We further investigated the inhibitory effects of curcumin on Aβ-
induced neuroinflammation in mixed neuronal/glial cultures.
Similarly, Aβ1–42 stimulation triggered the inflammatory
response, as indicated by elevated levels of TNF-α, IL-1β,
COX-2, and NO in the media. Activation of microglia and
astrocytes was also observed with increased GFAP and Iba-
1 immunoreactivity, as well as the expression of proteins.
Curcumin treatment significantly reduced the concentrations
of inflammatory mediators. Co-administration of GW9662 or
silencing of PPARγ by RNAi attenuated the anti-inflammatory
effects of curcumin (Figure 5). Combined with the results
of the in vivo study, these results suggest that the treatment
effects of curcumin on AD were closely related to its
inhibition of neuroinflammation, which might be mediated
by PPARγ.
Curcumin Suppressed the NF-κB Signaling
Pathway
Studies have shown that NF-κB signaling is involved in
inflammation and the immune response, including in the
brain. In APP/PS1 mice, IκB-α degradation, and NF-κB
p65 translocation were observed. However, pre-treatment
of curcumin decreased IκB-α degradation and NF-κB p65
translocation. The inhibitory effect of curcumin on IκB-α
degradation and NF-κB p65 translocation was counteracted by
co-administration of GW9662 (Figures 6A,B).
We then conducted in vitro experiments, in mixed
neuronal/glial cultures to confirm the in vivo results. Our
results demonstrate that increased IκB degradation and
NF-κB p65 translocation were stimulated by Aβ1–42, which
was inhibited by curcumin treatment (Figures 6C,D). Co-
administration of GW9662 or transfection with 25 nM PPARγ
siRNA attenuated the inhibitory effects of curcumin on NF-κB
signaling.
PPARγ has been reported to inhibit NF-κB activity. Thus,
we investigated the effect of PPARγ on NF-κB in mixed
neuronal/glial cells stimulated with Aβ. The data show that
PPARγ interacted with NF-κB p65 in curcumin-treated cells.
However, blocking of PPARγ with GW9662 or PPARγ siRNA
decreased the interaction of PPARγ with NF-κB p65 (Figure 6E)
suggesting that PPARγ signaling was involved in the suppression
of NF-κB activation in the neuroprotection of curcumin.
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FIGURE 4 | Curcumin suppressed neuroinflammatory response in APP/PS1 transgenic mice. Curcumin 150mg/kg and PPARγ inhibitor GW9662 4mg/kg
were i.p. injected to APP/PS1 double-transgenic mice for 4 consecutive weeks. (A) IL-1β level in hippocampus. (B) TNF-α level in hippocampus. (C) COX-2 level in
hippocampus. (D) NO level in hippocampus. Data were expressed as mean ± SD with six individual experiments. (E) Immunohistochemistry of GFAP in
hippocampus. (F) Immunohistochemistry of Iba-1 in hippocampus. Representative sections of hippocampus from five mice were shown. (G) Western blot of GFAP in
hippocampus. (H)Western blot of Iba-1 in hippocampus. A representative immunoblot from four mice was shown. Results were expressed as mean ± SD. *P < 0.05,
**P < 0.01 vs. WT mice, #P < 0.05, ##P < 0.01 vs. APP/PS1 transgenic mice, 1P < 0.05, 11P < 0.01 vs. curcumin treated mice.
Curcumin Improved PPARγ Function
The above data demonstrated that PPARγ was involved in the
anti-inflammatory effects of curcumin in vivo and in vitro.
Further experiments were conducted to investigate how PPARγ
participated in the anti-inflammatory process. PPARγ expression
and activity were obviously decreased in the hippocampi of
APP/PS1 mice. The same results were obtained in primary
mixed neuronal/glial cultures, suggesting that Aβ aggregation
deteriorated PPARγ function. Curcumin produced a two-fold
increase in PPARγ transcriptional activity, together with a
significant induction of PPARγ protein expression both in vivo
and in vitro (Figures 7A–D). These results suggest that curcumin
was a potent agent to promote PPARγ activity. Using CD
spectra technology, we further examined whether curcumin can
directly bind to PPARγ. The curve showed that 1µM curcumin
could directly bind PPARγ (Figure 7E), which may explain
why curcumin could improve PPARγ function. However, how
curcumin bind PPARγ need to be further investigation.
DISCUSSION
In this study, we performed a series of in vivo and in vitro
experiments demonstrating that curcumin could alleviate spatial
memory deficits and promote cholinergic neuronal function. The
beneficial effects of curcumin on AD were due to the suppression
of neuroinflammation, as indicated by the reduced activation
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FIGURE 5 | Curcumin inhibited neuroinflammation in mixed neuron/glia cultures. Mixed neuron/glia cultures were pre-treated with curcumin 10µM, 1 h later,
Aβ1–42 25µM was added to the mixed cultures. GW9662 1µM was added into the cultures or cells were transfected with PPARγ siRNA 1h before Aβ1–42
treatment. (A) IL-1β level of mixed neuron/glia cultures. (B) TNF-α level of mixed neuron/glia cultures. (C) COX-2 level of mixed neuron/glia cultures. (D) NO level of
mixed neuron/glia cultures. Data were expressed as mean ± SD with six individual experiments. (E) Immunofluorescence of GFAP. (F) Immunofluorescence of Mac-1.
Representative images from five experiments were shown. (G) Western blot of GFAP in mixed neuron/glia cultures. (H) Western blot of Iba-1 in mixed neuron/glia
cultures. A representative immunoblot from four independent experiments was shown. Data were expressed as mean ± SD. *P < 0.05, **P < 0.01 vs. control cells,
#P < 0.05, ##P < 0.01 vs. Aβ1–42-challenged cells,
1P < 0.05, 11P < 0.01 vs. curcumin treated cells.
of glia and cytokine production, as well as inhibition of the
NF-κB signaling pathway. In addition, this compound produced
a two-fold increase in PPARγ transcriptional activity, together
with a significant induction of PPARγ protein expression.
Notably, curcumin directly bound to PPARγ and upregulated
its function. These data together suggest that the modulation
of PPARγ activity by curcumin may contribute to alleviated
neuroinflammation and improved neuronal function.
Neuroinflammation associated with AD is often viewed as a
secondary response to Aβ deposition and neuronal death, but
plays a pivotal role in the pathogenesis and development of
AD (Amor et al., 2010). Microglia and astrocytes are activated
in response to Aβ, and they communicate with each other
in a bidirectional manner. Activated glia in senile plaques
can secrete vast amounts of pro-inflammatory mediators, such
as cytokines and chemokines, which are toxic to neurons
(Agostinho et al., 2010). It was reported that there were high
levels of IL-1β and TNF-α in brain and cerebrospinal fluid
of AD patients (Angelopoulos et al., 2008; Forlenza et al.,
2009), which provided evidence the role of inflammation in
the etiology of AD. In the animal model of AD, microglia
and astrocytes mediated neuroinflammation contribute the
production and formation of Aβ aggregates (Morales et al.,
2010). Thus, AD may possibly be treated by modulating glial
function and suppressing the inflammatory response in the
brain. A pharmacokinetics study showed that curcumin can
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FIGURE 6 | Curcumin suppressed NF-κB signaling pathway. Curcumin 150mg/kg and PPARγ inhibitor GW9662 4mg/kg were i.p. injected to APP/PS1
double-transgenic mice for 4 consecutive weeks. (A) IκB-α expression. (B) NF-κB p65 expression. Data were expressed as mean ± SD. Western blot images were
representative of four mice. Results were expressed as mean ± SD. *P < 0.05, **P < 0.01 vs. WT mice, #P < 0.05, vs. APP/PS1 transgenic mice, 1P < 0.05, vs.
curcumin treated mice. Mixed neuron/glia cultures were pre-treated with curcumin 10µM, 1 h later, Aβ1–42 25µM was added to the mixed cultures. GW9662 1µM
was added into the cultures or cells were transfected with PPARγ siRNA 1h before Aβ1–42 treatment. (C) IκB-α expression. (D) NF-κB p65 expression. Data were
expressed as mean ± SD. Western blot images were representative of four independent experiments. Results were expressed as mean ± SD. **P < 0.01 vs. control
cells, #P < 0.05, ##P < 0.01 vs. Aβ1–42-challenged cells,
1P < 0.05, 11P < 0.01 vs. curcumin treated cells. (E) Interaction of PPARγ and NF-κB p65.
cross the blood-brain barrier, where it is concentrated chiefly
in the hippocampus (Tsai et al., 2011). Moreover, curcumin is
a potent reagent for the treatment of AD (Wang et al., 2013).
In the present study, we demonstrated the robust activation
of astrogliosis and microgliosis, as well as a strong increase
in IL-1β, TNF-α, COX-2, and NO in the hippocampi of
APP/PS1 transgenic mice and mixed neuronal/glial cultures.
These findings confirm that the inflammatory response is
involved in the pathogenesis of AD. As expected, administration
of curcumin suppressed reactive gliosis as indicated by reducing
cytokine release. Given that neuroinflammation is important in
the development of neurodegenerative disease, the in vivo and
in vitro anti-inflammation of curcumin may provide additional
evidence of its therapeutic potential in AD.
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FIGURE 7 | Curcumin improved PPARγ function. Curcumin 150mg/kg and PPARγ inhibitor GW9662 4mg/kg were i.p. injected to APP/PS1 double-transgenic
mice for 4 consecutive weeks. (A) Western blot assay of PPARγ expression. The Western blot images were representative of four mice. (B) PPARγ transcriptional
activity assay. Data were expressed as mean ± SD with six individual experiments. *P < 0.05, **P < 0.01 vs. WT mice, #P < 0.05, vs. APP/PS1 transgenic mice, 1P
< 0.05, vs. curcumin treated mice. Mixed neuron/glia cultures were pre-treated with curcumin 10µM, 1 h later, Aβ1–42 25µM was added to the mixed cultures.
GW9662 1µM was added into the cultures or cells were transfected with PPARγ siRNA 1h before Aβ1–42 treatment. (C) Western blot assay of PPARγ expression.
The Western blot images were representative of four independent experiments. (D) PPARγ transcriptional activity assay. Data were expressed as mean ± SD with six
individual experiments. *P < 0.05, **P < 0.01 vs. control cells, #P < 0.05 vs. Aβ1–42-challenged cells,
1P < 0.05 vs. curcumin treated cells. (E) Circular dichroism
spectra of PPARγ (0.6µM, solid line) and curcumin/ PPARγ complex (dash line) at 37◦C.
The important role of PPARγ agonists in neuroprotection has
been extensively studied in neurodegeneration, such as in Aβ-
induced AD (Bright et al., 2008). Activation of PPARγ signaling
was shown to enhance Aβ uptake by microglia and thus improve
cognitive function in AD mice (Yamanaka et al., 2012). In our
previous study, we demonstrated that curcumin was a potent
agent for promoting PPARγ activity, which played a critical role
in protecting against cerebral ischemic injury because of its ability
to suppress the inflammatory response (Liu et al., 2013, 2014).
In the present study, curcumin elicited a two-fold increase in
the transcriptional activity of PPARγ and prompt expression of
PPARγ protein, thereby indicating the up-regulated activity of
PPARγ. Curcumin could directly bind to PPARγ protein, which
might be the basis of its anti-inflammatory activity. Moreover,
the reduction of NO, TNF-α, and IL-1β production by curcumin
was accompanied by the marked decline of GFAP and Iba-1
expression, which may correlate to the activation of PPARγ.
The observation that activation of PPARγ contributed to the
decrease in IκB degradation andNF-κB p65 protein translocation
further reinforced the importance of PPARγ on the inhibition of
NF-κB as responsible for curcumin’s anti-inflammatory effects.
Notably, PPARγ was involved in neuroprotective and anti-gliotic
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effects both in vivo and in vitro, because a loss in beneficial
activity occurred upon co-administration with PPARγ antagonist
GW9662 or blocking the expression of PPARγ by RNAi. Our
study confirmed previous reports that overexpression of PPARγ
can protect neurons from injury (Mandrekar-Colucci et al., 2012;
Jahrling et al., 2014). Therefore, PPARγ might be an important
mechanism responsible for the anti-inflammatory effects of
curcumin.
NF-κB plays a vital role in regulating of inflammation in many
diseases including brain injury and neurodegenerative diseases
(Song et al., 2004; Samuelsson et al., 2005). Study has shown that
curcumin could inhibit the activity of NF-κB through reducing
IκB-α degradation (Moon et al., 2006). Similarly, in the present
study, we observed significantly increased IκB-α degradation
and NF-κB p65 translocation in APP/PS1 mice and mixed
neuronal/glial cultures stimulated by Aβ, whereas curcumin
effectively reversed the activated NF-κB signaling. These results
suggest that the suppression of Aβ-triggered inflammation
by curcumin was through inhibition of the NF-κB signaling
pathway, which consistent with others studies demonstrating, the
inhibitory effects of PPARγ on NF-κB activation in different cell
systems. Activation of NF-κB is critically regulated at multiple
steps. In the current study, PPARγ physically interacted with
the NF-κB p65 subunit, blocked NF-κB activation, and inhibited
the dependent gene expression. Notably, PPARγ activation and
upregulation by curcumin were crucial to its inhibitory action on
NF-κB because the effects abated in part with co-administration
of GW9662 or silence of PPARγ. The present results confirmed
the results of our previous study, which showed that NF-κB
activity was inhibited by PPARγ in in vivo and in vitro cerebral
ischemic models. Moreover, the present data were supported by
the finding that PPARγ has been detected in the hippocampi
of adult rats (Moreno et al., 2004), and PPARγ activation is
reported to suppress inflammatory gene expression because of
the inhibition of NF-κB in animal models of brain damage
(Collino et al., 2006). Therefore, we speculated that activation of
PPARγ by curcumin may be a key step in inhibition of NF-κB
signaling pathway.
In summary, the curcumin data verified previous reports
demonstrating that neuroinflammation is risk factor in the
development of AD, and curcumin showed beneficial effects
on AD through suppressing such inflammatory response. The
present study demonstrated that the improvement of curcumin
on memory deficits in ADmight be through activation of PPARγ
pathway, which mitigates the neuroinflammatory response via
inhibiting the NF-κB signaling pathway.
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